Vimarsana
Biggest News Aggregation in the World

Page 17 - Small Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Small Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Small Pharma Today - Breaking & Trending Today

Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise - Vimarsana News

Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise

LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray drying and particle...

Small Pharma Announces Further Positive Data from SPL026 - Vimarsana News

Small Pharma Announces Further Positive Data from SPL026

-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers...

The Pulse: Psychedelic News From Technology Networks - Vimarsana News

The Pulse: Psychedelic News From Technology Networks

In the Pulse, the monthly psychedelics industry roundup from <i>Technology Networks </i> and <i>Analytical Cannabis</i>, we highlight some of the most significant psychedelic industry news from the past month. This includes important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

Almac Group Awarded with Six CDMO Leadership Awards Across all Core Categories - Vimarsana News

Almac Group Awarded with Six CDMO Leadership Awards Across all Core Categories

Almac Group, the global contract development and manufacturing organisation, is delighted to announce it has won six CDMO Leadership Awards for 2023. The CDMO Leadership Awards recognise top performing CDMOs, celebrating outstanding companies in drug development and manufacturing, emphasising high standards of ...

Small Pharma begins phase 1 mental health therapy trial - Vimarsana News

Small Pharma begins phase 1 mental health therapy trial

First subject dosed with company&rsquo;s SPL028 &ndash; a proprietary deuterated DMT candidate - News - PharmaTimes